^
    Back
    Association details:
    Biomarker:KRAS mutation
    Cancer:Colorectal Cancer
    Drug:ASN007 (ERK2 inhibitor, ERK1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

    Excerpt:
    ...- Have histologically or cytologically confirmed metastatic CRC harboring applicable mutation(s) (e.g., BRAF V600E; KRAS or NRAS mutations) or metastatic PDAC harboring KRAS mutation based on an analytically validated assay performed on tumor tissue in a certified testing laboratory....
    Trial ID:
    HERKULES-3
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study of ASN007 in Patients With Advanced Solid Tumors

    Excerpt:
    ...KRAS mutant CRC.(Part B)...
    Trial ID:
    NCT03415126
    Less C2 evidence
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR 2022
    Title:

    2672 / 15 - ­­­­ERAS-007 is a selective ERK1/2 inhibitor with preclinical activity across RAS/MAPK pathway-driven CRC models

    Published date:
    03/09/2022
    Excerpt:
    To this end, ERAS-007 was evaluated in preclinical models in combination with encorafenib + cetuximab in BRAFV600E CRC and with palbociclib in KRASmut CRC. ERAS-007 demonstrated monotherapy activity and combination benefit in cell-based assays as well as superior combination efficacy in vivo relative to respective monotherapy control arms.In summary, ERAS-007 demonstrates promising preclinical activity across a wide range of RAS/MAPK pathway-driven CRC models both as a monotherapy and in combination that support further exploration in the clinic.